![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RXRB |
Gene summary for RXRB |
![]() |
Gene information | Species | Human | Gene symbol | RXRB | Gene ID | 6257 |
Gene name | retinoid X receptor beta | |
Gene Alias | DAUDI6 | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0S2Z570 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6257 | RXRB | P127T-E | Human | Esophagus | ESCC | 4.41e-10 | 1.55e-01 | 0.0826 |
6257 | RXRB | P128T-E | Human | Esophagus | ESCC | 8.71e-38 | 9.01e-01 | 0.1241 |
6257 | RXRB | P130T-E | Human | Esophagus | ESCC | 8.52e-44 | 7.43e-01 | 0.1676 |
6257 | RXRB | HCC1_Meng | Human | Liver | HCC | 8.64e-18 | -5.25e-02 | 0.0246 |
6257 | RXRB | HCC2_Meng | Human | Liver | HCC | 6.23e-14 | 3.02e-02 | 0.0107 |
6257 | RXRB | HCC1 | Human | Liver | HCC | 1.00e-02 | 2.42e+00 | 0.5336 |
6257 | RXRB | HCC2 | Human | Liver | HCC | 8.85e-03 | 1.91e+00 | 0.5341 |
6257 | RXRB | Pt13.b | Human | Liver | HCC | 8.27e-06 | 5.46e-02 | 0.0251 |
6257 | RXRB | S014 | Human | Liver | HCC | 4.38e-07 | 4.16e-01 | 0.2254 |
6257 | RXRB | S015 | Human | Liver | HCC | 1.89e-11 | 6.79e-01 | 0.2375 |
6257 | RXRB | S016 | Human | Liver | HCC | 6.20e-13 | 5.31e-01 | 0.2243 |
6257 | RXRB | S027 | Human | Liver | HCC | 1.93e-02 | 4.47e-01 | 0.2446 |
6257 | RXRB | S029 | Human | Liver | HCC | 6.56e-04 | 2.04e-01 | 0.2581 |
6257 | RXRB | C04 | Human | Oral cavity | OSCC | 6.40e-09 | 5.09e-01 | 0.2633 |
6257 | RXRB | C21 | Human | Oral cavity | OSCC | 1.34e-19 | 7.77e-01 | 0.2678 |
6257 | RXRB | C30 | Human | Oral cavity | OSCC | 1.68e-13 | 7.83e-01 | 0.3055 |
6257 | RXRB | C38 | Human | Oral cavity | OSCC | 4.13e-11 | 1.28e+00 | 0.172 |
6257 | RXRB | C43 | Human | Oral cavity | OSCC | 6.08e-14 | 2.43e-01 | 0.1704 |
6257 | RXRB | C46 | Human | Oral cavity | OSCC | 8.60e-20 | 4.59e-01 | 0.1673 |
6257 | RXRB | C57 | Human | Oral cavity | OSCC | 3.02e-04 | 3.14e-01 | 0.1679 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003052220 | Esophagus | HGIN | intracellular receptor signaling pathway | 62/2587 | 265/18723 | 1.63e-05 | 4.50e-04 | 62 |
GO:004854527 | Esophagus | HGIN | response to steroid hormone | 73/2587 | 339/18723 | 6.06e-05 | 1.40e-03 | 73 |
GO:007138320 | Esophagus | HGIN | cellular response to steroid hormone stimulus | 44/2587 | 204/18723 | 1.56e-03 | 1.79e-02 | 44 |
GO:00483844 | Esophagus | HGIN | retinoic acid receptor signaling pathway | 11/2587 | 31/18723 | 2.02e-03 | 2.12e-02 | 11 |
GO:004340118 | Esophagus | HGIN | steroid hormone mediated signaling pathway | 31/2587 | 136/18723 | 3.01e-03 | 2.88e-02 | 31 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
GO:004340119 | Esophagus | ESCC | steroid hormone mediated signaling pathway | 87/8552 | 136/18723 | 1.25e-05 | 1.15e-04 | 87 |
GO:000975516 | Esophagus | ESCC | hormone-mediated signaling pathway | 106/8552 | 190/18723 | 3.13e-03 | 1.30e-02 | 106 |
GO:004838412 | Esophagus | ESCC | retinoic acid receptor signaling pathway | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
GO:00325261 | Esophagus | ESCC | response to retinoic acid | 63/8552 | 107/18723 | 4.05e-03 | 1.62e-02 | 63 |
GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
GO:004854522 | Liver | HCC | response to steroid hormone | 206/7958 | 339/18723 | 6.81e-12 | 2.92e-10 | 206 |
GO:007138322 | Liver | HCC | cellular response to steroid hormone stimulus | 128/7958 | 204/18723 | 3.92e-09 | 1.04e-07 | 128 |
GO:004340121 | Liver | HCC | steroid hormone mediated signaling pathway | 84/7958 | 136/18723 | 4.42e-06 | 5.62e-05 | 84 |
GO:000975521 | Liver | HCC | hormone-mediated signaling pathway | 106/7958 | 190/18723 | 1.45e-04 | 1.17e-03 | 106 |
GO:00483841 | Liver | HCC | retinoic acid receptor signaling pathway | 20/7958 | 31/18723 | 1.11e-02 | 4.09e-02 | 20 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0521620 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa05417114 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa05216110 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa052229 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0521628 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa046599 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0492816 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0465914 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0492817 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RXRB | SNV | Missense_Mutation | rs754055760 | c.1501C>T | p.Arg501Trp | p.R501W | P28702 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RXRB | SNV | Missense_Mutation | c.881N>A | p.Gly294Glu | p.G294E | P28702 | protein_coding | deleterious(0.01) | possibly_damaging(0.468) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
RXRB | SNV | Missense_Mutation | novel | c.1016N>G | p.Ile339Ser | p.I339S | P28702 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | c.484N>T | p.Ile162Phe | p.I162F | P28702 | protein_coding | tolerated(0.07) | probably_damaging(0.979) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RXRB | SNV | Missense_Mutation | c.1363N>A | p.Ala455Thr | p.A455T | P28702 | protein_coding | deleterious(0.05) | probably_damaging(0.942) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
RXRB | SNV | Missense_Mutation | c.433N>G | p.Leu145Val | p.L145V | P28702 | protein_coding | tolerated(0.26) | probably_damaging(0.973) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RXRB | SNV | Missense_Mutation | novel | c.242N>A | p.Arg81Gln | p.R81Q | P28702 | protein_coding | tolerated_low_confidence(0.07) | benign(0.005) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | novel | c.77N>C | p.Lys26Thr | p.K26T | P28702 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | c.1340N>T | p.Ala447Val | p.A447V | P28702 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RXRB | SNV | Missense_Mutation | c.706N>T | p.Asp236Tyr | p.D236Y | P28702 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | TRETINOIN | TRETINOIN | ||
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | CHEMBL1131 | ACITRETIN | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | antagonist | 135651303 | ||
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | modulator | CHEMBL146506 | MOFAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | TAZAROTENE | TAZAROTENE | ||
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | antagonist | 135650518 | ||
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650520 | BEXAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | ALITRETIONINE | |||
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | CHEMBL1023 | BEXAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | BEXAROTENE | BEXAROTENE |
Page: 1 2 3 |